Neurophysiological signatures of Stanford Neuromodulation Therapy in treatment resistant depression
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
Stanford Neuromodulation Therapy (SNT) has demonstrated impressive efficacy for treatment-resistant depression (TRD), but its neurophysiological mechanisms remain poorly understood. This study investigated the neurophysiological correlates of SNT using transcranial magnetic stimulation with electroencephalography (TMS-EEG).
Method
A double-blind, randomized, sham-controlled clinical trial was conducted at Stanford University. Twenty-four participants with TRD (12 active, 12 sham) received TMS-EEG measurements at baseline, before/after each treatment day across the 5-day protocol, and at 1-month follow-up. The intervention consisted of active or sham SNT protocol (10 daily sessions of intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex over 5 consecutive days). Main outcome measures included TMS-evoked potentials (a measure of cortical excitability) at both the L-DLPFC (treatment site) and vertex Cz (control site), and sgACC source-localized activation.
Results
Active SNT progressively reduced cortical excitability specifically at the treatment site, with significant reduction observed by day 3 (N45 [early negative component at ∼45ms]: -27.9%, p<0.01; P200 [late positive component at ∼200ms]: -39.8%, p<0.001), while no changes occurred at the control site (Cz) in either group (all p>0.05). This spatial specificity was confirmed by direct site comparisons showing significant reductions only at the L-DLPFC target (t(22)=-3.8, p<0.001). Additionally, active SNT significantly reduced sgACC responses to TMS across sessions (F(13,222)=4.93, p<0.001), with effects persisting at 1-month follow-up. Critically, baseline sgACC activation predicted treatment response (r=-0.67, p=0.023), with higher baseline activation associated with greater clinical improvement.
Conclusions
SNT produces progressive, site-specific modulation of TMS-evoked potentials (cortical excitability) at the targeted L-DLPFC and selective reduction in sgACC activation, with neurophysiological changes mirroring clinical improvement. The spatial specificity of effects confirms target-specific neuroplasticity. Baseline sgACC activity and changes in cortical excitability early in treatment represent promising biomarkers for personalizing TMS treatment for depression.
